Almac’s Predictive Assay for Immuno-Oncology

This gene expression based assay identifies a molecular subgroup of cancers that exhibit activation of immune checkpoint proteins such as PD-L1 and ID01, which results in immune system evasion and cancer cell survival.

Almac is developing this assay as a means of prospectively identifying patients likely to respond to PD-L1 targeted therapies.


This assay has the potential to be used as a companion diagnostic for immune checkpoint inhibitor based therapy across a range of disease areas.

Validation of the underlying biology which connects immune checkpoint activation to DNA damage has been published in the Journal of the National Cancer Institute.

Contact Us

Related resources